Innovation in surgical and diagnostic care gained traction this week, marked by major investments across robotics, AI, and neurotechnology. Cornerstone Robotics’ latest raise highlights the accelerating shift toward more capable and accessible robotic surgery, while Beacon Biosignals continues to push AI-driven brain monitoring into clinical reality. Momentum in sleep apnea neuromodulation and predictive cancer analytics further emphasizes a clear trend: intelligent, data-powered devices are transforming how-and how early-patients receive care.
Cornerstone Robotics raises $200M for endoscopic surgical robot platform
The financing included investments from a global strategic investor, some global institutional or sovereign wealth funds and existing shareholders. The company plans to use funds to accelerate commercialization efforts and continue innovating in surgical robotics.
This funding accelerates its mission to make safe, efficient and accessible surgical robotic technologies available to healthcare providers worldwide.
Founder and CEO Samuel Au
Last week’s tracker: Synchron, Precision Neuroscience & more
Beacon Biosignals raises $86M to support AI-driven EEG wearable
A syndicate of healthcare and technology investors, including Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio Capital Management and Takeda led the round. General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures participated, too.
The financing brings the company’s total funding to more than $121 million to date. It supports its AI-driven brain biomarker technology.
Co-founder and CEO Jacob Donoghue
Nyxoah raises $77M to support Genio sleep apnea neuromod rollout
The company announced private equity placements and registered direct offerings that combine with a convertible bond financing of up to $52 million, amounting to up to $77 million.
With the proceeds, the company plans to support commercialization efforts for its Genio system in the U.S. Genio utilizes an implanted electrode around the hypoglossal nerve, stimulating the tongue and keeping the airway open to treat obstructive sleep apnea.
CEO Olivier Taelman
Clairity raises $43M to launch AI platform for breast cancer risk prediction
The round was led by ACE Global Equity and Santé Ventures, with continued participation from the Breast Cancer Research Foundation (BCRF) and several new investors.
The new funding will allow Clairity to accelerate U.S. commercialization, expand partnerships with leading imaging centers and health systems, and drive continued development of Clairity’s broader predictive health platform.
President and CEO Jeff Luber
HRS Navigation secures $5M funding to expand surgical navigation technology
The Pre-Series A funding round was led by GVFL, Physis Capital, Sathguru Catalysers, India EXIM Bank, and KITVEN. The investment will support product innovation, scale manufacturing, and expand the startup’s presence in international markets.
The easyNav platform has facilitated over 20,000 surgeries, enabling surgeons to perform procedures with enhanced precision and confidence.
Founder Arpit Paliwal
Laronix Secures $2.1M Grant to bring its AI-powered voice technology to the market
The company secured the non-dilutive funding from the Australian Government’s Industry Growth Program (IGP 2025).
The grant will support product refinement, clinical testing, and early commercial rollout – bringing MIRA Voice and its personalized MIRA-AI voice technology closer to the millions of patients affected by voice loss each year.
CEO Farzaneh Ahmadi
